检测梅毒螺旋体DNA用于男男性行为者早期梅毒的诊断、耐药鉴定和治疗结局预测
研究前瞻性纳入2021年9月至2024年8月就诊的男男性行为者,检测口腔冲洗液、直肠拭子和尿道拭子中的梅毒螺旋体DNA(TP-DNA),并分析大环内酯类和四环素类耐药相关突变及治疗反应。TP-DNA检测特异性99.3%,敏感性45.7%;检出TP-DNA者治疗6个月和12个月血清学反应率均高于未检出者;大环内酯类耐药突变率为58.9%。作者认为应避免使用阿奇霉素治疗梅毒。
要点
- 口腔冲洗液TP-DNA检出率最高(37.8%),其次为直肠拭子(20.2%)和尿道拭子(11.6%)。
- TP-DNA诊断早期梅毒特异性99.3%,敏感性45.7%,二期梅毒检出率最高(67.6%)。
- 大环内酯类耐药突变率58.9%,从2021年32.4%升至2023年77.8%。
核心结论
- 梅毒螺旋体PCR对早期梅毒诊断特异性高,与RPR滴度和治疗反应相关,口腔冲洗液Ct值越低与RPR滴度越高相关。
- 大环内酯类耐药突变高流行,作者认为在台湾应避免使用阿奇霉素治疗梅毒。
研究设计与样本
- 前瞻性纳入2021年9月至2024年8月因性传播感染就诊的男男性行为者(MSM),共656例。
- 检测口腔冲洗液、直肠拭子和尿道拭子中的TP-DNA,鉴定大环内酯类和四环素类耐药相关突变。
- 比较检出与未检出TP-DNA的梅毒病例的治疗反应。
主要发现
- 在早期梅毒临床就诊中,TP-DNA检出率口腔冲洗液为37.8%(193/510),直肠拭子为20.2%(103/510),尿道拭子为11.6%(59/510)。
- 早期梅毒病例TP-DNA检出率为45.7%(233/510),无梅毒病例为0.7%(1/141),特异性99.3%(95% CI: 96.1-100%),敏感性45.7%(95% CI: 41.3-50.1%)。
- 二期梅毒TP-DNA检出率最高(67.6% [117/173]),其次为一期(48.7% [19/39])和早期潜伏梅毒(32.6% [97/298])。
- 口腔冲洗液梅毒螺旋体PCR的Ct值在RPR滴度较高病例中显著更低(p < 0.001)。
- 大环内酯类耐药相关突变率为58.9%(139/236),从2021年32.4%(12/37)升至2023年77.8%(21/27)。
关键数值与推荐
- TP-DNA检测早期梅毒特异性99.3%(95% CI: 96.1-100%),敏感性45.7%(95% CI: 41.3-50.1%)。
- 大环内酯类耐药突变率58.9%(139/236)。
临床怎么用
- 作者认为在台湾应避免使用阿奇霉素治疗梅毒。
- 梅毒螺旋体PCR可用于早期梅毒诊断,口腔冲洗液Ct值与RPR滴度和治疗反应相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We investigated the use of Treponema pallidum DNA (TP-DNA) for diagnosis, resistance identification, and treatment outcome prediction in early syphilis among men who have sex with men (MSM). METHODS: MSM seeking care for sexually transmitted infections were prospectively enrolled from September 2021 to August 2024. Oral rinse, rectal swab, and urethral swab samples were tested for TP-DNA. Resistance-associated mutations (RAMs) to macrolides and tetracyclines were identified. Treatment responses were compared between syphilis cases with detected TP-DNA and those without. RESULTS: Of 656 MSM enrolled, TP-DNA was most frequently detected in oral rinse samples (37.8% [193/510]), followed by rectal swab (20.2% [103/510]) and urethral swab samples (11.6%, 59/510) in clinic visits for early syphilis. TP-DNA was detected in 45.7% (233/510) of early syphilis cases and 0.7% (1/141) of cases without syphilis, resulting in a specificity of 99.3% (95% CI: 96.1-100%) and sensitivity of 45.7% (95% CI: 41.3-50.1%). Secondary syphilis cases had the highest yield of TP-DNA detection (67.6% [117/173]), followed by primary (48.7% [19/39]) and early latent syphilis cases (32.6% [97/298]). The Ct values of T. pallidum PCR in oral rinse samples were significantly lower in cases of higher rapid plasma reagin (RPR) titres (p < 0.001). The rate of T. pallidum harbouring RAMs to macrolides was 58.9% (139/236), increasing over 6-month intervals, from 32.4% (12/37) in 2021 to 77.8% (21/27) in 2023. Cases of detected TP-DNA had greater serological responses to treatments than those without: 80.3% (159/198) vs. 67.0% (156/233) at month 6 (p 0.002) and 84.1% (143/170) vs. 70.3% (137/195) at month 12 (p = 0.002). DISCUSSION: T. pallidum PCR showed high specificity for the diagnosis of early syphilis, which correlated with RPR titres and treatment response, and lower Ct values in oral rinse samples correlated with higher RPR titres. The high prevalence of T. pallidum strains with RAMs to macrolides argues against using azithromycin to treat syphilis in Taiwan.
引用
- Wu TY, Lin KY, Sun HY, et al. Detection of Treponema pallidum DNA for diagnosis, resistance identification, and treatment outcome prediction in early syphilis among men who have sex with men. Clin Microbiol Infect. 2025. PMID: 39978634. doi:10.1016/j.cmi.2025.02.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。